Neurizon Therapeutics (ASX: NUZ) has received approval from the Bellberry Human Research Ethics Committee for a Phase 1 study of its NUZ-001 oral liquid formulation.
The approval marks a significant regulatory step to enhance patient accessibility and treatment continuity for its Amyotrophic Lateral Sclerosis (ALS) candidate.
The study, to be conducted in Australia, will enrol 32 healthy volunteers in a randomised, four-arm design and compare the oral liquid formulation against the tablet form under both fed and fasted conditions.
Crucially, the trial aims to gather vital pharmacokinetic, safety, and tolerability data, as well as explore biomarkers and assess palatability.
Neurizon targets study initiation in Q3 CY2026, with completion anticipated by Q4 CY2026.
Oral Formulation Addresses Patient Needs
The development of an oral liquid formulation for NUZ-001 is a strategic move to improve patient accessibility and flexibility in administration.
This is particularly important for patients with ALS, where disease progression often leads to dysphagia, or swallowing difficulties.
The liquid form aims to ensure continuous treatment.
This new formulation programme works alongside Neurizon's ongoing participation in the pivotal HEALEY ALS Platform Trial in the United States.
Broader NUZ-001 Development Context
NUZ-001 is currently undergoing evaluation in Regimen I of the HEALEY ALS Platform Trial, an adaptive Phase 2/3 study.
Earlier preclinical data for NUZ-001 and its sulfone metabolite indicated an ability to increase activity across multiple neuronal protein clearance pathways.
These pathways are highly relevant in neurodegenerative diseases such as ALS.
Previous studies have also highlighted NUZ-001's potential to provide significant blood-brain barrier penetration and strong safety characteristics in human brain models.
Recent Capital and Leadership Updates
In recent corporate developments, Neurizon Therapeutics successfully raised A$2.657 million by securing firm commitments for a partial placement of its entitlement offer shortfall.
This injection of capital is intended to strengthen its balance sheet and support NUZ-001's Phase 2/3 clinical development.
The company is also navigating a leadership transition, following the resignation of its Managing Director and CEO, Dr Michael Thurn.
Sergio Duchini has stepped into the role of interim Executive Chair, overseeing operations while a global search for a new CEO is conducted.
